Antiangiogenic drugs targeting the VEGF signaling pathway have been approved in the treatment for NSCLC patients by means of successful clinical trials (Johnson et al, 2004; Sandler et al, 2006; Cohen et al, 2007; Reck et al, 2009). The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.